President Lee Jae Myung discussed North Korea's nuclear issue with Trump at the G7, proposing a phased approach for resolution.

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

iM Securities predicts a rebound in South Korea's stock market due to Trump's exit strategy from the Iran conflict, despite ongoing tensions.